Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets
The global market for circulating tumor cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.
- An overview of the global market for cancer diagnostics based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
- Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates for the period of 2013 to 2018.
- Discussion of the advantages and disadvantages of CTC enrichment techniques.
- Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
- Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.
SCOPE OF THE STUDY
The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical segment, currently approved CTC tests and their markets, the regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area. This report does not include the segment’s research market including reagents, or any accessories used for CTC isolation or studies. The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies. The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.
ABOUT THE AUTHOR
Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.